Home - Products - Others - Other Targets - DL-Buthionine-(SR)-sulfoximine

DL-Buthionine-(SR)-sulfoximine

CAS No. 5072-26-4

DL-Buthionine-(SR)-sulfoximine( Butionine sulfoximine | NSC 381100 )

Catalog No. M20963 CAS No. 5072-26-4

DL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 31 In Stock
50MG 43 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DL-Buthionine-(SR)-sulfoximine
  • Note
    Research use only, not for human use.
  • Brief Description
    DL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.
  • Description
    DL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Butionine sulfoximine | NSC 381100
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    γ-glutamylcysteine synthetase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    5072-26-4
  • Formula Weight
    222.31
  • Molecular Formula
    C8H18N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:41.67 mg/mL (187.44 mM; Need ultrasonic)
  • SMILES
    CCCCS(=N)(=O)CCC(N)C(=O)O
  • Chemical Name
    2-amino-4-(butylsulfonimidoyl)butanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Arrick B. A . Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis[J]. Journal of Experimental Medicine 1981 153(3):720-725.
molnova catalog
related products
  • u-Conotoxin GIIIA

    u-Conotoxin GIIIA

  • Tetracosane

    Tetracosane is a natural product isolated from the Bangladeshi medicinal plant Acrostichum aureum.

  • IXA6

    IXA6, a novel IRE1/XBP1s agonist with potential vasoprotective activity, activates IRE1-XBP1s signaling and XBP1s transcriptional response, making it useful for studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.